Akebia Therapeutics, Inc. (AKBA)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 295 | 212 | 292 | 195 | 160 | 236 | 219 | 198 |
| Operating profit | $m | 23 | -15 | ||||||
| Net profit | $m | -385 | -282 | -94 | -52 | -69 | -5 | -30 | -36 |
| EPS reported | $ | -0.02 | -0.11 | ||||||
| Operating cashflow per share | $ | 0.26 | 0.15 | ||||||
| Capex per share | $ | 0.00 | 0.01 | ||||||
| FCF per share | $ | 0.26 | 0.15 | ||||||
| Free cash flow | $m | 68 | 40 | ||||||
| Net debt | $m | 31 | -106 | ||||||
| Book value equity | $m | 33 | 25 | ||||||
| Book value per share | $ | 0.13 | 0.09 | ||||||
| Number of shares | m | 257.16 | 269.6 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 12.70 | 16.55 | ||||||
| P/S LTM | x | 1.75 | 1.89 | ||||||
| P/FCF LTM | x | 6.09 | 10.29 | ||||||
| EV/EBITDA LTM | x | 20.50 | -24.73 | ||||||
| EV/Sales LTM | x | 1.89 | 0.73 | ||||||
| Earnings Yield LTM | % | -1.29% | -11.29% | ||||||
| FCF Yield | % | +16.42% | +9.72% | ||||||
| Quality | |||||||||
| ROE | % | -16.39% | -93.74% | ||||||
| ROIC | % | +9.26% | -7.08% | ||||||
| Operating margin | % | +9.95% | -6.91% | ||||||
| Gross margin | % | +83.29% | +79.48% | ||||||
| FCF/Sales | % | +28.79% | +18.37% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +47.46% | +36.76% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.31 | 0.75 | ||||||
| Net Debt/EBITDA | x | 1.45 | 5.64 | ||||||
| EBIT/Net interest | x | 0.97 | -1.90 | ||||||
| Net debt/market cap | % | +52.24% | +18.96% | ||||||
| Net debt/Equity | x | 0.96 | -4.24 | ||||||
| Gross debt/equity | x | 6.63 | 2.16 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free